Shots:
- The DSMB recommended the P-I/II clinical trial of AMT-130 in patients with Huntington’s disease, after reviewing safety data from the four patients in the higher-dose cohort
- In Aug’21, the company has completed enrollment in the second, higher-dose cohort in the P-I/II clinical trial of AMT-130 in 14 patients out of which eight patients received treatment with AMT-130 and six patients received imitation surgery for early manifest HD. The company is expected to complete the full enrollment in mid-2022 in the higher-dose cohort
- The company plans to initiate the P-III study of the therapy in the EU and share initial imaging and biomarker data from the US clinical trial at the end of 2021
Click here to read the full press release/ article | Ref: Globe Newswire | Image: Fd.nl
The post uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease first appeared on PharmaShots.
